{"title": "Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase", "doi": "10.1101/2020.03.18.997585", "citation_id": "2020.03.18.997585v1", "date": "2020-03-20", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.03.18.997585", "abstract": "<p>SARS-CoV-2, a member of the coronavirus family, is responsible for the current COVID-19 pandemic. Based on our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously demonstrated that three nucleotide analogues inhibit the SARS-CoV RNA-dependent RNA polymerase (RdRp). Here, using polymerase extension experiments, we have demonstrated that the active triphosphate form of Sofosbuvir (a key component of the FDA approved hepatitis C drug EPCLUSA), is incorporated by SARS-CoV-2 RdRp, and blocks further incorporation. Using the same molecular insight, we selected the active triphosphate forms of three other anti-viral agents, Alovudine, AZT (an FDA approved HIV/AIDS drug) and Tenofovir alafenamide (TAF, an FDA approved drug for HIV and hepatitis B) for evaluation as inhibitors of SARS-CoV-2 RdRp. We demonstrated the ability of these three viral polymerase inhibitors, 3\u2032-fluoro-3\u2032-deoxythymidine triphosphate, 3\u2032-azido-3\u2032-deoxythymidine triphosphate and Tenofovir diphosphate (the active triphosphate forms of Alovudine, AZT and TAF, respectively) to be incorporated by SARS-CoV-2 RdRp, where they also terminate further polymerase extension. These results offer a strong molecular basis for these nucleotide analogues to be evaluated as potential therapeutics for COVID-19.</p>", "twitter_description": "SARS-CoV-2, a member of the coronavirus family, is responsible for the current COVID-19 pandemic. Based on our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously demonstrated that three nucleotide analogues inhibit the SARS-CoV RNA-dependent RNA polymerase (RdRp). Here, using polymerase extension experiments, we have demonstrated that the active triphosphate form of Sofosbuvir (a key component of the FDA approved hepatitis C drug EPCLUSA), is incorporated by SARS-CoV-2 RdRp, and blocks further incorporation. Using the same molecular insight, we selected the active triphosphate forms of three other anti-viral agents, Alovudine, AZT (an FDA approved HIV/AIDS drug) and Tenofovir alafenamide (TAF, an FDA approved drug for HIV and hepatitis B) for evaluation as inhibitors of SARS-CoV-2 RdRp. We demonstrated the ability of these three viral polymerase inhibitors, 3\u2032-fluoro-3\u2032-deoxythymidine triphosphate, 3\u2032-azido-3\u2032-deoxythymidine triphosphate and Tenofovir diphosphate (the active triphosphate forms of Alovudine, AZT and TAF, respectively) to be incorporated by SARS-CoV-2 RdRp, where they also terminate further polymerase extension. These results offer a strong molecular basis for these nucleotide analogues to be evaluated as potential therapeutics for COVID-19.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/20/2020.03.18.997585.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.03.18.997585v1", "access_rights": "restricted", "authors": ["Minchen Chien", "Thomas K. Anderson", "Steffen Jockusch", "Chuanjuan Tao", "Shiv Kumar", "Xiaoxu Li", "James J. Russo", "Robert Kirchdoerfer", "Jingyue Ju"]}